EQUIVALENCE RATIO FOR DAUNORUBICIN TO DOXORUBICIN IN RELATION TO LATE HEART FAILURE

Elizabeth AM Feijen MS¹, Wendy Leisenring ScD², Kayla L Stratton MS², Kirsten K Ness PhD³, Helena JH Van der Pal MD PhD ¹,4, Huib N Caron MD PhD¹, Gregory T Armstrong MD MSCE³, Daniel M Green MD³, Melissa M Hudson MD³, Kevin C Oeffinger MD⁵, Leslie L Robison PhD², Marilyn Stovall PhD⁶, Leontien CM Kremer MD PhD¹, Eric J Chow MD MPH².

Author affiliations
¹ Emma Children’s Hospital / Academic Medical Center, Amsterdam, The Netherlands
² Fred Hutchinson Cancer Research Center, Seattle (WA), USA
³ St Jude Children’s Research Hospital, Memphis (TN), USA
⁴ Academic Medical Center, Amsterdam, The Netherlands
⁵ Memorial Sloan Kettering Cancer Center, New York (NY), USA
⁶ University of Texas, MD Anderson Cancer Center, Houston (TX), USA

Corresponding author: E.A.M Feijen; Department of Pediatric Oncology, Emma Children’s Hospital/ Academic Medical Center, Amsterdam, the Netherlands; Telephone number:0031 20 566 1417; Email address: e.a.feijen@amc.uva.nl.

Presentation: Oral

Purpose
Based on hematologic toxicity data, the anthracycline dose equivalence ratio between daunorubicin and doxorubicin has typically been assumed to be 1:1. However, there is no consensus on an optimal equivalence ratio with respect to cardiac toxicity among childhood cancer survivors. We sought to determine the optimal equivalence ratio for daunorubicin to doxorubicin based on the risk of clinical heart failure (HF) in this population.

Patients and methods
Data from 15,815 survivors in four childhood cancer survivor cohorts were used: Emma Children’s Hospital/Academic Medical Center (n=1,349), the National Wilms Tumor Study (n=365), the St. Jude Lifetime Cohort Study (n=1,695), and the Childhood Cancer Survivor Study (n=12,407). The hazard ratio (HR) for clinical HF through age 40 years for daunorubicin and doxorubicin doses (per 100 mg/m² increments) was estimated using Cox regression, adjusted for gender, age at diagnosis, treatment with any of other anthracycline agents, chest radiation, and cohort membership.

Results
The pooled study population had a median follow-up time of 17.3 years (range 0-35.0) since cohort entry. In total, 5,144 (32.5%) patients received doxorubicin while 2,243 (14.7%) patients received daunorubicin. Based on 271 HF cases, the cumulative incidence of HF at age 40 for the entire pooled cohort was 3.2% (95% Confidence Interval [CI] 2.8-3.7%). The average equivalence ratio of daunorubicin to doxorubicin HRs in increments of 100 mg/m² was 0.45 (95% CI 0.23-0.73). A similar equivalence ratio was obtained when the association between each agent and HF was modeled using a linear dose-response model, 0.49 (95% CI 0.28-0.70).

Conclusion
Compared with doxorubicin, daunorubicin appeared substantially less cardiotoxic among childhood cancer survivors than most current guidelines suggest. This may have implications for follow-up guidelines. Assuming similar cancer therapeutic efficacy, the feasibility of substituting doxorubicin with less cardiotoxic daunorubicin in childhood cancer treatment protocols should be investigated further.